Everything below concerns dual agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
== Entrepreneurship, Outreach, and Advocacy == Bhatia is a prolific inventor, holding more than 65 issued or pending patents for clinical and biotechnological applications of engineering principles over twenty years. Her entrepreneurial ventures include:
=== Surgery === Either Aetius in the sixth century CE or Persian Ali ibn Abbas al-Magusi in 990 CE conducted the first recorded thyroidectomy as a treatment for goitre. Operations remained risky and generally were not successful until the 19th century, when descriptions emerged from a number of authors including Prussian surgeon Theodor Billroth, Swiss surgeon and physiologist Theodor Kocher, American physician Charles Mayo, American surgeons William Halsted and George Crile. These descriptions provided the basis for modern thyroid surgery. Theodor Kocher went on to win the Nobel Prize in Physiology or Medicine in 1909 "for his work on the physiology, pathology and surgery of the thyroid gland".
Examples of membrane-spanning protein phosphatases containing both active (phosphatase) and inactive (pseudophosphatase) domains linked in tandem are known, conceptually similar to the kinase and pseudokinase domain polypeptide structure of the JAK pseudokinases. A complete comparative analysis of human phosphatases and pseudophosphatases has been completed by Manning and colleagues, forming a companion piece to the ground-breaking analysis of the human kinome, which encodes the complete set of ~536 human protein kinases.
==== Post-mastectomy fat-graft reconstruction ==== The reconstruction of the breast(s) with grafts of autologous fat is a non-implant alternative to further surgery after a breast cancer surgery, be it a lumpectomy or a breast removal – simple (total) mastectomy, radical mastectomy, modified radical mastectomy, skin-sparing mastectomy, and subcutaneous (nipple sparing) mastectomy. The breast is reconstructed by first applying external tissue expansion to the recipient-site tissues (adipose, glandular) to create a breast-tissue matrix that can be injected with autologous fat grafts (adipocyte tissue); the reconstructed breast has a natural form, look, and feel, and is generally sensate throughout and in the nipple-areola complex (NAC). The reconstruction of breasts with fat grafts requires a three-month treatment period – begun after 3–5 weeks of external vacuum expansion of the recipient-site tissues. The autologous breast-filler fat is harvested by liposuction from the patient's body (buttocks, thighs, abdomen), is refined and then is injected (grafted) to the breast-tissue matrices (recipient sites), where the fat will thrive. One method of non-implant breast reconstruction is initiated at the concluding steps of the breast cancer surgery, wherein the oncological surgeon is joined by the reconstructive plastic surgeon, who immediately begins harvesting, refining, and seeding (injecting) fat grafts to the post-mastectomy recipient site.
Sources: en.wikipedia.org
=== Frameshift === A recessive frameshift mutation resulting in a reduction of leptin has been observed in two consanguineous children with juvenile obesity. A 2001 study of 13 people with a heterozygous frameshift mutation known as delta-G133 found that they had lower blood leptin levels than controls. There was an increased rate of obesity in these individuals, with 76% having a BMI of more than 30 compared to 26% in the control group.
The verdict was treated with scepticism by much of the international media and the US Government led by President Jimmy Carter. On 2 February 1978, based on the evidence given at the inquest, the attorney general of the Eastern Cape stated that he would not prosecute the officers. After the inquest, Biko's family brought a civil case against the state; at the advice of their lawyers, they agreed to a settlement of R65,000 (US$78,000) in July 1979. Shortly after the inquest, the South African Medical and Dental Council initiated proceedings against the medical professionals who had been entrusted with Biko's care; eight years later two of the medics were found guilty of improper conduct. The failure of the government-employed doctors to diagnose or treat Biko's injuries has been frequently cited as an example of a repressive state influencing medical practitioners' decisions, and Biko's death as evidence of the need for doctors to serve the needs of patients before those of the state. After the abolition of apartheid and the establishment of a majority government in 1994, a Truth and Reconciliation Commission was established to investigate past human-rights abuses. The commission made plans to investigate Biko's death, but his family petitioned against this on the grounds that the commission could grant amnesty to those responsible, thereby preventing the family's right to justice and redress. In 1996, the Constitutional Court ruled against the family, allowing the investigation to proceed.
ENGERIX-B (produced by GSK) and RECOMBIVAX HB (produced by merck) are two recombinant subunit vaccines licensed for the protection against hepatitis B. Both contain HBsAg harvested and purified from Saccharomyces cerevisiae and are formulated as a suspension of the antigen adjuvanted with alum. Antibody concentration ≥10mIU/mL against HBsAg are recognized as conferring protection against hepatitis B infection. It has been shown that primary 3-dose vaccination of healthy individuals is associated with ≥90% seroprotection rates for ENGERIX-B, despite decreasing with older age. Lower seroprotection rates are also associated with presence of underlying chronic diseases and immunodeficiency. Yet, GSK HepB still has a clinically acceptable safety profile in all studied populations.
Trump stated that if he were elected, he would increase deportations, send the U.S. military to the border, expand U.S. Immigration and Customs Enforcement detentions through workplace raids, deputize local law enforcement to handle border security, increase U.S. Customs and Border Protection funding, as well as finish building the wall on the southern border. Trump has said he will deport both legal and illegal immigrants. The New York Times reported that Trump was considering "an extreme expansion of his first-term crackdown on immigration", such as "preparing to round up undocumented people already in the United States on a vast scale and detain them in sprawling camps while they wait to be expelled". Trump stated his intention to deport 11 million people through the construction of detention camps and deploy the military, relying on presidential wartime powers under the 18th-century Alien Enemies Act. Trump made false claims of a "migrant crime wave" that are not supported by data, and provided no evidence to back up his claims. In regards to his anti-immigrant nativism, Trump's tone grew harsher from his previous time as president, and used fearmongering, racial stereotypes, and more dehumanizing rhetoric when referring to illegal immigrants.
Nicotinamide N-methyltransferase (NNMT) is an enzyme that in humans is encoded by the NNMT gene. NNMT catalyzes the methylation of nicotinamide and similar compounds using the methyl donor S-adenosyl methionine (SAM-e) to produce S-adenosyl-L-homocysteine (SAH) and 1-methylnicotinamide.
Sources: en.wikipedia.org
===== Macroscopic viscous flow ===== Macroscopic viscous flow fields can direct self-assembly of a random solution of particles into ordered crystals via the shear-assisted nucleation mechanism. However, the flow-induced self-assembly often occurs far from thermodynamic equilibrium and leads to amorphous aggregates of nanoparticles through a mechanism by which the shear flow field overcomes the repulsive energy barrier which stabilizes the nanoparticles against self-assembly in the absence of flow. The assembled particles aggregates tend to disassemble due to flow-induced breakup or when the flow is stopped or removed if the interparticle bonds are weak. Shear flows are also useful for jammed suspensions or random close packing. As these systems begin in nonequilibrium conditions, flow fields are useful in that they help the system relax towards a more ordered equilibrium. Flow fields are also useful when dealing with complex matrices that themselves exhibit rheological behavior. Flow can induce anisotropic viseoelastic stresses, which helps to overcome the matrix and cause self-assembly.
==== Effect on bacteria ==== Silver nanoparticles are experimentally shown to inhibit autotrophic nitrifying bacterial growth (86±3%) more than Ag+ ions (42±7%) or AgCl colloids (46±4%). Silver nanoparticle-inhibited heterotrophic growth (55±8%) in Escherichia coli is best observed at lower concentrations, between 1.0 uM and 4.2 uM. This is less than Ag+ ions (~100%), but greater than AgCl colloids (66±6%). The actual cause of these results is undetermined as growth conditions and cell properties differ between nitrifying bacteria and heterotrophic E. coli. Studies conducted in natural lake environments show less response from bacterioplankton than in laboratory environments when exposed to similar concentrations of silver nanoparticles. This may be due to the binding of free Ag+ ions to dissolved organic matter in lake environments, rendering the Ag+ unavailable. Within toothpaste, Ag+ ions have been shown to have a stronger effect on gram-negative bacteria than on gram-positive bacteria. In comparison to other nanoparticles, such as gold, silver tends to have a broader antimicrobial effect, which is another reason why it is incorporated into so many products. Ag+ is less effective on gram-positive bacteria due to the thick layer of peptidoglycan around them that gram-negative species lack. Approximately half of the peptidoglycan wall is composed of teichoic acids linked by phosphodiester bonds, which results in an overall negative charge in the peptidoglycan layer.
== Medical use == Axatilimab is indicated for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in people weighing at least 40 kilograms (88 lb).
Weapons-grade nuclear material is any fissionable nuclear material that is pure enough to make a nuclear weapon and has properties that make it particularly suitable for nuclear weapons use. Plutonium and uranium in grades normally used in nuclear weapons are the most common examples. (These nuclear materials have other categorizations based on their purity.) Only fissile isotopes of certain elements have the potential for use in nuclear weapons. For such use, the concentration of fissile isotopes uranium-235 and plutonium-239 in the element used must be sufficiently high. Uranium from natural sources is enriched by isotope separation, and plutonium is produced in a suitable nuclear reactor. Experiments have been conducted with uranium-233 (the fissile material at the heart of the thorium fuel cycle). Neptunium-237 and some isotopes of americium might be usable, but it is not clear that this has ever been implemented. The latter substances are part of the minor actinides in spent nuclear fuel.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。